Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration
Trevor E. Angell, Melissa G. Lechner, Julie K. Jang, et al.
Thyroid (2014) Vol. 24, Iss. 9, pp. 1385-1393
Open Access | Times Cited: 119

Showing 26-50 of 119 citing articles:

Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Jena D. French, Bryan R. Haugen, Francis P. Worden, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 17, pp. 3757-3767
Closed Access | Times Cited: 8
PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma
Matthew W. Rosenbaum, Benjamin J. Gigliotti, Sara I. Pai, et al.
Endocrine Pathology (2018) Vol. 29, Iss. 1, pp. 59-67
Open Access | Times Cited: 57
Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer
Silvia Cantara, Eugenio Bertelli, Rossella Occhini, et al.
Endocrine (2019) Vol. 64, Iss. 1, pp. 122-129
Closed Access | Times Cited: 53
PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population
Yalan Bi, Xinyu Ren, Xiaohui Bai, et al.
European Journal of Surgical Oncology (2018) Vol. 45, Iss. 3, pp. 353-358
Closed Access | Times Cited: 51
BRAFV600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis
Kaixuan Zeng, Zhe Wang, Koichi Ohshima, et al.
OncoImmunology (2016) Vol. 5, Iss. 7, pp. e1185582-e1185582
Open Access | Times Cited: 48
Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma
Ilaria Girolami, Liron Pantanowitz, Özgür Mete, et al.
Endocrine Pathology (2020) Vol. 31, Iss. 3, pp. 291-300
Closed Access | Times Cited: 48
PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications
Salvatore Ulisse, Chiara Tuccilli, Salvatore Sorrenti, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 6, pp. 1405-1405
Open Access | Times Cited: 44
What is the status of immunotherapy in thyroid neoplasms?
Alejandro García‐Álvarez, Jorge Hernando, Ana Carmona-Alonso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 27
Very low expression of PD-L1 in medullary thyroid carcinoma
Massimo Bongiovanni, Caterina Rebecchini, Chiara Saglietti, et al.
Endocrine Related Cancer (2017) Vol. 24, Iss. 6, pp. L35-L38
Open Access | Times Cited: 47
PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
Yanhua Bai, Dongfeng Niu, Xiaozheng Huang, et al.
Diagnostic Pathology (2017) Vol. 12, Iss. 1
Open Access | Times Cited: 44
Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types
Giosuè Scognamiglio, A. Chiara, Maurizio Di Bonito, et al.
International Journal of Molecular Sciences (2016) Vol. 17, Iss. 5, pp. 790-790
Open Access | Times Cited: 41
From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer
Grégoire D’Andréa, Sandra Lassalle, N. Guevara, et al.
Theranostics (2020) Vol. 11, Iss. 3, pp. 1310-1325
Open Access | Times Cited: 37
Immune Microenvironment of Thyroid Cancer
Hongyu Yin, Yemei Tang, Yujia Guo, et al.
Journal of Cancer (2020) Vol. 11, Iss. 16, pp. 4884-4896
Open Access | Times Cited: 36
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies
María San Román, Javier Pozas, Diana Rosero-Rodríguez, et al.
Cancer Treatment Reviews (2022) Vol. 105, pp. 102372-102372
Closed Access | Times Cited: 22
Cell Component and Function of Tumor Microenvironment in Thyroid Cancer
Eunah Shin, Ja Seung Koo
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12578-12578
Open Access | Times Cited: 21
PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy
Monikongkona Boruah, Pranitha Gaddam, Shipra Agarwal, et al.
Journal of Cancer Research and Therapeutics (2023) Vol. 19, Iss. 2, pp. 312-320
Open Access | Times Cited: 11
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers
Liya Zhu, Xiu Juan Li, Prakash Gangadaran, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 12, pp. 3895-3917
Open Access | Times Cited: 11
Emerging roles of circular RNAs in regulating the hallmarks of thyroid cancer
Tianjiao Zhou, Zheng Li, Yumeng Jiang, et al.
Cancer Gene Therapy (2024) Vol. 31, Iss. 4, pp. 507-516
Open Access | Times Cited: 4
Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way
Lucas Leite Cunha, Marjory Alana Marcello, Vinícius Rocha-Santos, et al.
Endocrine Related Cancer (2017) Vol. 24, Iss. 12, pp. T261-T281
Open Access | Times Cited: 39
In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related
Yanhua Bai, Ting Guo, Xiaozheng Huang, et al.
Virchows Archiv (2018) Vol. 472, Iss. 5, pp. 779-787
Closed Access | Times Cited: 35
PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by BRAFV600E Mutation
Abdul K. Siraj, Sandeep Kumar Parvathareddy, Poyil Pratheeshkumar, et al.
Cancers (2021) Vol. 13, Iss. 3, pp. 555-555
Open Access | Times Cited: 24
BRAFV600E mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs
Zhi Jie, Xiaojing Jia, Jing Yan, et al.
World Journal of Gastrointestinal Oncology (2021) Vol. 13, Iss. 12, pp. 2129-2148
Open Access | Times Cited: 24
Roles and new Insights of Macrophages in the Tumor Microenvironment of Thyroid Cancer
Qi Liu, Wei Sun, Hao Zhang
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 17
Prognostic Characterization of Papillary Thyroid Carcinoma: Insights into the Role of PD-L1 and Mutational Landscape in Disease Aggressiveness and Outcome
Chanchal Rana, Prabhakar Mishra, Isha Makkar, et al.
Research Square (Research Square) (2025)
Closed Access
Dynamic Changes in Lymphocyte Subsets and Inflammation-Immune-Related Proteins in Patients with Thyroid Papillary Carcinoma before and after Radioactive Iodine Therapy
Junyu Zhang, Lulu Shi, Zhilin Zhang, et al.
Journal of Proteome Research (2025)
Closed Access

Scroll to top